首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1407302

细胞免疫治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按治疗类型、适应症、最终用途、地区、竞争细分

Cellular Immunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy Type, By Indication, By End-Use, By Region, By Competition

出版日期: 2023年11月07日 | 出版商:

TechSci Research | 英文 171 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022 年全球细胞免疫治疗市场价值为 64.3 亿美元，预计在预测期内将强劲增长，到 2028 年复合CAGR为 9.31%。推动市场增长的一些主要因素是先进细胞疗法的开发、癌症疾病率上升以及主要公司增加研发投资。此外，越来越多的产品批准和越来越多地采用这些疗法来治疗癌症正在推动市场成长。强大的产品线预计将推动市场成长。根据癌症研究所（CRI）2020年报告，约有1,483种免疫疗法药物正在进行临床试验，比前一年增加约472种新的临床试验候选药物。此外，根据 NCBI 研究，大多数处于开发阶段的疗法都是自体（人类细胞）的。然而，近年来同种异体（现成）疗法显着增加。

主要市场驱动因素

癌症发生率增加

市场概况
预测期	2024-2028
2022 年市场规模	64.3亿美元
2028 年市场规模	108.8亿美元
2023-2028 年CAGR	9.31%
成长最快的细分市场	医院
最大的市场	北美洲

癌症发生率的不断上升有望成为推动全球细胞免疫治疗市场成长轨蹟的关键催化剂。随着全球癌症诊断数量持续激增，对先进且有效的治疗解决方案的需求不断增长。细胞免疫疗法的特点是利用人体自身免疫系统来对抗癌症的创新方法，在这场战斗中脱颖而出，成为一个充满希望的前沿领域。各种癌症类型的盛行率不断上升，凸显了对针对性和个人化治疗方式的迫切需求，从而将细胞免疫疗法定位为最前沿的竞争者。这种尖端技术通常涉及提取和修饰患者自身的免疫细胞以增强其抗癌能力，为对抗多种癌症提供了客製化且有效的途径。此外，医疗保健专业人员和患者对细胞免疫疗法潜在益处的认识不断提高，预计将推动市场采用。随着研发工作的加强和监管审批的简化，全球细胞免疫治疗市场有望大幅扩张，这与解决全球癌症负担不断升级的迫切需求一致。这些因素的结合使细胞免疫疗法成为不断发展的肿瘤治疗领域的关键参与者，促进了市场的强劲成长。

市场规模及预测
- 按价值
市占率及预测
- 依治疗类型（CAR T 细胞疗法、树突细胞疗法、NK 细胞疗法、TIL 疗法等）
- 依适应症（B 细胞恶性肿瘤、前列腺癌、肝癌、肾细胞癌、其他）
- 依最终用途（医院、癌症研究所、其他）
- 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
- 按公司划分 (2022)
市场地图
- 按治疗类型
- 按指示
- 按最终用途
- 按地区

第 6 章：北美细胞免疫治疗市场展望

市场规模及预测
- 按价值
市占率及预测
- 依治疗类型（CAR T 细胞疗法、树突细胞疗法、NK 细胞疗法、TIL 疗法等）
- 依适应症（B 细胞恶性肿瘤、前列腺癌、肝癌、肾细胞癌、其他）
- 依最终用途（医院、癌症研究所、其他）
- 按国家/地区
北美：国家分析
- 美国
- 加拿大
- 墨西哥

第 7 章：欧洲细胞免疫治疗市场展望

市场规模及预测
- 按价值
市占率及预测
- 依治疗类型（CAR T 细胞疗法、树突细胞疗法、NK 细胞疗法、TIL 疗法等）
- 依适应症（B 细胞恶性肿瘤、前列腺癌、肝癌、肾细胞癌、其他）
- 依最终用途（医院、癌症研究所、其他）
- 按国家/地区
欧洲：国家分析
- 法国
- 德国
- 英国
- 义大利
- 西班牙

第 8 章：亚太细胞免疫治疗市场展望

市场规模及预测
- 按价值
市占率及预测
- 依治疗类型（CAR T 细胞疗法、树突细胞疗法、NK 细胞疗法、TIL 疗法等）
- 依适应症（B 细胞恶性肿瘤、前列腺癌、肝癌、肾细胞癌、其他）
- 依最终用途（医院、癌症研究所、其他）
- 按国家/地区
亚太地区：国家分析
- 中国
- 印度
- 日本
- 韩国
- 澳洲

第 9 章：南美洲细胞免疫疗法市场展望

市场规模及预测
- 按价值
市占率及预测
- 依治疗类型（CAR T 细胞疗法、树突细胞疗法、NK 细胞疗法、TIL 疗法等）
- 依适应症（B 细胞恶性肿瘤、前列腺癌、肝癌、肾细胞癌、其他）
- 依最终用途（医院、癌症研究所、其他）
- 按国家/地区
南美洲：国家分析
- 巴西
- 阿根廷
- 哥伦比亚

第 10 章：中东和非洲细胞免疫疗法市场展望

市场规模及预测
- 按价值
市占率及预测
- 依治疗类型（CAR T 细胞疗法、树突细胞疗法、NK 细胞疗法、TIL 疗法等）
- 依适应症（B 细胞恶性肿瘤、前列腺癌、肝癌、肾细胞癌、其他）
- 依最终用途（医院、癌症研究所、其他）
- 按国家/地区
MEA：国家分析
- 南非细胞免疫疗法
- 沙乌地阿拉伯细胞免疫疗法
- 阿联酋细胞免疫疗法

第 11 章：市场动态

司机
挑战

第 12 章：市场趋势与发展

近期发展
併购
产品发布

第 13 章：全球细胞免疫治疗市场：SWOT 分析

第 14 章：波特的五力分析

产业竞争
新进入者的潜力
供应商的力量
客户的力量
替代产品的威胁

第15章：竞争格局

百时美施贵宝公司。
- Business Overview
- Product Offerings
- Recent Developments
- Financials (As Reported)
- Key Personnel
- SWOT Analysis
诺华公司。
吉利德科学公司（Kite Pharma）
F.霍夫曼-拉罗氏有限公司
默克公司。
葛兰素史克公司
阿斯特捷利康公司
辉瑞公司
强生公司。
塞利亚德。

第 16 章：策略建议

简介目录

Product Code: 20046

Global Cellular Immunotherapy Market has valued at USD 6.43 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.31% through 2028. Some of the major factors propelling the market growth are the development of advanced cell-based therapies, the rising prevalence of cancer, and increasing R&D investment by key companies. Moreover, the increasing number of product approvals and growing adoption of these therapies for the treatment of cancer is boosting the market growth. A robust product pipeline is expected to propel the market growth. According to the Cancer Research Institute (CRI) 2020 report, around 1,483 immunotherapy agents are there in clinical trials, with a rise of about 472 new clinical trial candidates than the previous year. In addition, according to the NCBI research studies, most therapies in the developmental phase are autologous (person's cells). However, there has been a significant rise in allogeneic (off-the-shelf) therapies in recent years.

Key Market Drivers

Increasing Incidence of Cancer

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 6.43 Billion
Market Size 2028	USD 10.88 Billion
CAGR 2023-2028	9.31%
Fastest Growing Segment	Hospitals
Largest Market	North America

The escalating incidence of cancer is poised to be a pivotal catalyst propelling the growth trajectory of the Global Cellular Immunotherapy Market. As cancer diagnoses continue to surge globally, there is a burgeoning demand for advanced and effective therapeutic solutions. Cellular immunotherapy, characterized by its innovative approach harnessing the body's own immune system to combat cancer, stands out as a promising frontier in this battle. The rising prevalence of various cancer types underscores the urgent need for targeted and personalized treatment modalities, positioning cellular immunotherapy as a forefront contender. This cutting-edge technology, often involving the extraction and modification of a patient's own immune cells to enhance their cancer-fighting capabilities, offers a bespoke and potent avenue for combating the diverse array of cancers. Furthermore, the increasing awareness among healthcare professionals and patients about the potential benefits of cellular immunotherapy is expected to drive market adoption. As research and development efforts intensify, and regulatory approvals streamline, the Global Cellular Immunotherapy Market is poised for substantial expansion, aligning with the imperative to address the escalating global cancer burden. This confluence of factors positions cellular immunotherapy as a pivotal player in the evolving landscape of oncological treatments, fostering robust market growth.

Advancements in Technology and Research

The burgeoning growth of the Global Cellular Immunotherapy Market is intricately linked to continuous advancements in technology and research. Breakthroughs in cellular biology, genetic engineering, and immunology are catalyzing the development of sophisticated cellular immunotherapy solutions. Cutting-edge technologies enable the manipulation and modification of immune cells with unprecedented precision, enhancing their efficacy in targeting and eliminating cancer cells. Furthermore, ongoing research endeavors contribute to the expansion of the therapeutic spectrum, identifying novel targets and optimizing treatment protocols. The exploration of advanced biomarkers and genetic markers allows for a more personalized and tailored approach to cellular immunotherapy, augmenting its effectiveness across a diverse range of cancers. The convergence of artificial intelligence, big data analytics, and high-throughput screening techniques accelerates the discovery and optimization of cellular therapies. This integration not only expedites the development process but also ensures a more cost-effective and scalable production of these innovative treatments. As technology continues to evolve, fostering a deeper understanding of the intricacies of the immune system and cancer biology, the Global Cellular Immunotherapy Market is poised for remarkable expansion. These technological strides not only enhance the therapeutic efficacy but also contribute to the market's competitiveness, driving sustained growth in the dynamic landscape of cellular immunotherapy.

Rising Acceptance of Personalized Medicine

The escalating acceptance of personalized medicine is poised to be a driving force behind the growth of the Global Cellular Immunotherapy Market. As healthcare transitions towards a more individualized treatment paradigm, cellular immunotherapy emerges as a linchpin in this transformative shift. The inherent ability of cellular immunotherapy to tailor treatments to a patient's specific genetic and molecular profile aligns seamlessly with the principles of personalized medicine. Patients and healthcare professionals increasingly recognize the limitations of traditional, one-size-fits-all approaches to cancer treatment. The rising demand for therapies that are precisely calibrated to an individual's unique biology and the characteristics of their cancer propels the adoption of cellular immunotherapy. By harnessing the body's own immune system, these therapies exhibit a level of specificity and effectiveness that resonates with the personalized medicine ethos. The convergence of technological advancements, genetic profiling, and a deeper understanding of cancer biology amplifies the feasibility and acceptance of personalized cellular immunotherapies. Consequently, as the global healthcare landscape prioritizes individualized care, the Global Cellular Immunotherapy Market stands to benefit substantially, positioning itself as a cornerstone in the era of personalized medicine. This trend is anticipated to fuel sustained market growth, meeting the evolving expectations of patients and practitioners alike.

Key Market Challenges

High Development Costs

The growth trajectory of the Global Cellular Immunotherapy Market faces a notable impediment in the form of high development costs. The intricate nature of cellular immunotherapy, involving cutting-edge technologies and rigorous clinical testing, entails substantial financial investments at every stage of the development pipeline. From initial research and preclinical studies to large-scale clinical trials and regulatory approvals, the expenses associated with bringing cellular immunotherapies to market are considerable. These elevated development costs pose a significant barrier for companies, both large and small, entering the cellular immunotherapy arena. The financial burden can limit the number of entities capable of undertaking such ventures, potentially restricting the diversity of innovative therapies brought to market. Additionally, the protracted timelines inherent in the development and approval process further compound the financial challenges, potentially deterring investment and slowing market growth. Moreover, the high costs associated with manufacturing and scaling up production processes for personalized cellular therapies contribute to the overall economic challenges. As a result, despite the immense therapeutic potential of cellular immunotherapy, the market growth may be constrained by the formidable financial demands, necessitating strategic collaborations, funding mechanisms, and streamlined regulatory pathways to overcome this hurdle and unlock the full potential of these groundbreaking therapies.

Adverse Events and Safety Concerns

The growth trajectory of the Global Cellular Immunotherapy Market confronts a formidable challenge in the form of adverse events and safety concerns. As cellular immunotherapy involves manipulating the patient's own immune cells to combat diseases like cancer, there exists a potential for unforeseen adverse reactions. The intricate interplay between the modified cells and the patient's physiology introduces a level of complexity that can give rise to unexpected safety issues.

Instances of severe side effects or adverse events observed during clinical trials or post-market surveillance can trigger regulatory scrutiny, impacting market access and dampening investor confidence. The necessity for stringent safety monitoring protocols and risk mitigation strategies adds an additional layer of complexity to the development and commercialization process, potentially leading to prolonged timelines and increased development costs. Furthermore, adverse events can undermine patient and healthcare provider confidence in cellular immunotherapies, affecting their adoption rates. The market's growth is intricately tied to establishing the safety profile of these therapies, necessitating transparent communication, robust safety monitoring mechanisms, and continuous research to address and minimize potential risks. In navigating these challenges, the Global Cellular Immunotherapy Market must prioritize comprehensive safety assessments and proactively address concerns to build and maintain trust among stakeholders. Achieving a balance between innovation and safety will be pivotal in overcoming these hurdles and fostering sustained market growth.

Key Market Trends

Expansion Beyond Oncology

The expansion beyond oncology is poised to be a key driver propelling the growth of the Global Cellular Immunotherapy Market. While cellular immunotherapy initially gained prominence in cancer treatment, the recognition of its potential extends beyond oncology to a spectrum of diseases. Researchers and companies are exploring applications in autoimmune disorders, infectious diseases, and other therapeutic areas, broadening the market's scope. Diversifying the applications of cellular immunotherapy not only opens up new avenues for therapeutic intervention but also mitigates the market's reliance on a singular therapeutic domain. As the understanding of the immune system's role in various health conditions deepens, leveraging cellular immunotherapy for non-oncological indications presents a strategic opportunity for market expansion. This strategic diversification enhances the market's resilience, as advancements in cellular immunotherapy for non-oncological applications can contribute to a more stable revenue stream and attract a wider range of investors. Additionally, it aligns with the broader trend in healthcare towards holistic and targeted therapeutic approaches.

Allogeneic Cell Therapies

Allogeneic cell therapies are poised to be a significant catalyst driving the growth of the Global Cellular Immunotherapy Market. Unlike autologous cell therapies that use a patient's own cells, allogeneic cell therapies utilize cells from a healthy donor, allowing for a more scalable and cost-effective production process. This shift in approach overcomes some of the logistical challenges associated with personalized medicine, thereby broadening accessibility to a larger patient population. The allogeneic model not only streamlines manufacturing processes but also accelerates time-to-market, as ready-made cellular products can be made available for immediate use. This efficiency contributes to a more commercially viable and competitive landscape within the cellular immunotherapy market. Furthermore, allogeneic cell therapies offer the potential for off-the-shelf treatments, reducing the need for complex patient-specific manufacturing and minimizing treatment delays. This approach addresses the limitations associated with autologous therapies, such as variability in cell quality and the time-consuming nature of individualized production. As the field advances, the adoption of allogeneic cell therapies is expected to significantly impact the market, fostering broader patient access and contributing to the overall growth and sustainability of the Global Cellular Immunotherapy Market.

Segmental Insights

Indication Insights

Based on the Indication, the B-cell Malignancies segment is anticipated to witness substantial market growth throughout the forecast period. The growth of the Global Cellular Immunotherapy Market is anticipated to be significantly propelled by the treatment of B-cell malignancies. Cellular immunotherapy, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, has demonstrated remarkable efficacy in addressing B-cell malignancies such as certain types of leukemia and lymphomas. These therapies involve the genetic modification of a patient's T cells to express chimeric receptors, enabling them to recognize and eliminate B-cell cancers with precision. The specificity of cellular immunotherapy for B-cell malignancies addresses a critical unmet medical need, especially in cases resistant to conventional treatments. The success of CAR-T therapies in achieving deep and durable responses in patients with relapsed or refractory B-cell malignancies has positioned these interventions as groundbreaking treatments. As research continues to refine and expand the application of cellular immunotherapy for B-cell malignancies, including exploring combination therapies and addressing potential challenges like durability and safety, the market is poised for sustained growth. The increasing incidence of B-cell malignancies and the evolving landscape of cancer treatment contribute to the promising outlook for the Global Cellular Immunotherapy Market, with B-cell malignancies playing a central role in driving its expansion.

End-Use Insights

Based on the End-Use segment, the Hospital Pharmacies segment has been the dominant force in the market. Cancer institutes are poised to play a pivotal role in propelling the growth of the Global Cellular Immunotherapy Market. These specialized institutions, dedicated to advancing cancer research and treatment, serve as epicenters for innovation, collaboration, and clinical trials focused on cellular immunotherapies. Their expertise in understanding the intricacies of cancer biology and their access to diverse patient populations position cancer institutes as critical players in driving advancements in cellular immunotherapy. Collaborative efforts between cancer institutes and biopharmaceutical companies foster the development of novel cellular immunotherapies. The infrastructure and resources within these institutes accelerate the translation of groundbreaking research into clinical applications, expediting the pathway to regulatory approvals and commercialization. Moreover, cancer institutes often serve as hubs for training healthcare professionals in the administration and management of cellular immunotherapies, ensuring widespread adoption and dissemination of best practices. Their influence extends beyond research and development, as they contribute to shaping treatment guidelines and protocols, influencing regulatory decisions, and raising awareness about the transformative potential of cellular immunotherapy. In essence, the symbiotic relationship between cancer institutes and the Global Cellular Immunotherapy Market is poised to drive innovation, accelerate therapeutic breakthroughs, and ultimately contribute significantly to the market's growth and the advancement of cancer care on a global scale.

Regional Insights

North America, specifically the Cellular Immunotherapy Market, dominated the market in 2022, primarily due to The North America region is poised to be a primary driver of the growth in the Global Cellular Immunotherapy Market. The region's prominence is attributed to a confluence of factors, including robust research and development infrastructure, a high prevalence of cancer, and a favorable regulatory environment. Leading biopharmaceutical companies and research institutions in the United States and Canada are at the forefront of pioneering cellular immunotherapy research, contributing significantly to the market's innovation and advancement. Moreover, the North American healthcare ecosystem's readiness to adopt cutting-edge therapies and its well-established clinical trial infrastructure further accelerate the development and commercialization of cellular immunotherapies. The region's patient-centric approach and sophisticated healthcare delivery systems enhance the accessibility and adoption of these novel treatments. Strategic collaborations between industry players, academic institutions, and healthcare providers in North America drive efficient clinical development and facilitate market penetration. Additionally, favorable reimbursement policies and a supportive regulatory landscape foster a conducive environment for market growth. Given these factors, North America stands as a key hub for cellular immunotherapy, serving as both a major market for existing therapies and a hotbed for continued research and development, thereby propelling the overall growth of the Global Cellular Immunotherapy Market.

Key Market Players

Bristol-Myers Squibb Company.

Novartis AG.

Gilead Sciences Inc. (Kite Pharma)

F. Hoffmann-La Roche Ltd.

Merck KGaA.

GlaxoSmithKline plc.

AstraZeneca Plc.

Pfizer Inc.

Johnson & Johnson.

Celyad.

Report Scope:

In this report, the Global Cellular Immunotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cellular Immunotherapy Market, By Therapy Type:

CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others

Cellular Immunotherapy Market, By Indication:

B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others

Cellular Immunotherapy Market, By End-Use:

Hospitals
Cancer Institutes
Others

Cellular Immunotherapy Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cellular Immunotherapy Market.

Available Customizations:

Global Cellular Immunotherapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cellular Immunotherapy Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
- 5.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
- 5.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
- 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.5. By Company (2022)
5.3. Market Map
- 5.3.1 By Therapy Type
- 5.3.2 By Indication
- 5.3.3 By End-Use
- 5.3.4 By Region

6. North America Cellular Immunotherapy Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
- 6.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
- 6.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Cellular Immunotherapy Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapy Type
    - 6.3.1.2.2. By Indication
    - 6.3.1.2.3. By End-Use
- 6.3.2. Canada Cellular Immunotherapy Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapy Type
    - 6.3.2.2.2. By Indication
    - 6.3.2.2.3. By End-Use
- 6.3.3. Mexico Cellular Immunotherapy Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapy Type
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By End-Use

7. Europe Cellular Immunotherapy Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
- 7.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
- 7.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Cellular Immunotherapy Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapy Type
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By End-Use
- 7.3.2. Germany Cellular Immunotherapy Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapy Type
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By End-Use
- 7.3.3. United Kingdom Cellular Immunotherapy Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapy Type
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By End-Use
- 7.3.4. Italy Cellular Immunotherapy Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapy Type
    - 7.3.4.2.2. By Indication
    - 7.3.4.2.3. By End-Use
- 7.3.5. Spain Cellular Immunotherapy Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapy Type
    - 7.3.5.2.2. By Indication
    - 7.3.5.2.3. By End-Use

8. Asia-Pacific Cellular Immunotherapy Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
- 8.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
- 8.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Cellular Immunotherapy Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapy Type
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By End-Use
- 8.3.2. India Cellular Immunotherapy Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapy Type
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By End-Use
- 8.3.3. Japan Cellular Immunotherapy Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapy Type
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By End-Use
- 8.3.4. South Korea Cellular Immunotherapy Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapy Type
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By End-Use
- 8.3.5. Australia Cellular Immunotherapy Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapy Type
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By End-Use

9. South America Cellular Immunotherapy Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
- 9.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
- 9.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Cellular Immunotherapy Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapy Type
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By End-Use
- 9.3.2. Argentina Cellular Immunotherapy Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapy Type
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By End-Use
- 9.3.3. Colombia Cellular Immunotherapy Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapy Type
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By End-Use

10. Middle East and Africa Cellular Immunotherapy Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
- 10.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
- 10.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Cellular Immunotherapy Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapy Type
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By End-Use
- 10.3.2. Saudi Arabia Cellular Immunotherapy Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapy Type
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By End-Use
- 10.3.3. UAE Cellular Immunotherapy Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapy Type
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By End-Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Cellular Immunotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Bristol-Myers Squibb Company.
- 15.1.1. Business Overview
- 15.1.2. Product Offerings
- 15.1.3. Recent Developments
- 15.1.4. Financials (As Reported)
- 15.1.5. Key Personnel
- 15.1.6. SWOT Analysis
15.2. Novartis AG.
15.3. Gilead Sciences Inc. (Kite Pharma)
15.4. F. Hoffmann-La Roche Ltd.
15.5. Merck KGaA.
15.6. GlaxoSmithKline plc.
15.7. AstraZeneca Plc.
15.8. Pfizer Inc.
15.9. Johnson & Johnson.
15.10. Celyad.